Fuda Cancer Hospital
Fuda Cancer Hospital
Chine, Canton
| Chine | Turquie | Espagne | |
| Chimiothérapie intrapéritonéale hyperthermique (HIPEC) | de $22,500 | de $22,500 | de $25,000 |
Bookimed ne rajoute pas de frais pour les traitements de Сarcinomatose. Les tarifs proviennent des listes de prix officielles des cliniques. Vous payez directement à la clinique pour votre traitement à votre arrivée dans le pays.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans le traitement de Сarcinomatose et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de traitement de Сarcinomatose.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
China utilizes cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy as the primary protocol for carcinomatosis. The procedure involves removing visible tumors before circulating heated medicine into the abdominal cavity. This integrated approach often combines Western surgical standards with traditional therapies to manage side effects and inflammation.
Bookimed Expert Insight: Chinese oncology clinics like Fuda Cancer Hospital offer alternatives to standard systemic chemotherapy. These centers specialize in combining hyperthermic treatments with over 10 types of minimally invasive therapies. This approach is useful for patients seeking options beyond traditional aggressive resection. Accreditation by Joint Commission International ensures these facilities follow standardized protocols for international patients from over 100 countries.
Patient Consensus: Patients emphasize that this aggressive surgery is not a universal solution for everyone. Success depends heavily on receiving a second opinion to verify disease burden and primary tumor type.
Beijing Shijitan Hospital and Fuda Cancer Hospital lead Chinas treatment for peritoneal carcinomatosis. These centers utilize cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Specialized teams manage advanced abdominal malignancies. JCI-accredited facilities often provide integrated multi-modal care for international patients.
Bookimed Expert Insight: China is a unique destination for late-stage abdominal cancers. Centers like Fuda Cancer Hospital have served over 30,000 international patients. Clinical teams often accept advanced cases that other global institutions may decline. This high volume allows surgeons to maintain proficiency in complex debulking procedures.
Patient Consensus: Patients note that Chinese doctors often consider surgery for cases deemed inoperable elsewhere. It is important to provide full pathology reports and PET scans before travel.
Traditional Chinese Medicine (TCM) is integrated into carcinomatosis care strictly as a supportive therapy. Chinese oncology centers combine herbal formulas and acupuncture with Hyperthermic Intraperitoneal Chemotherapy (HIPEC). This integrative approach aims to reduce fluid buildup and alleviate chemotherapy side effects. TCM never replaces surgical or interventional treatments.
Bookimed Expert Insight: Data shows leading facilities like Fuda Cancer Hospital emphasize minimally invasive technologies over traditional chemo. They utilize NanoKnife and cryosurgery alongside supportive care for advanced stages. This suggests that in China, the value of TCM lies in helping patients physically tolerate these high-tech interventions. Integrating TCM within JCI-accredited hospitals ensures better safety than using standalone alternative clinics.
Patient Consensus: Patients note that integrated hospital teams are more trustworthy for managing herb-drug interactions. They highlight the importance of using TCM specifically for appetite and comfort rather than seeking it as a primary cure.
Chinese oncology centers utilize domestically developed, proprietary platforms like the BR-TRG series for HIPEC delivery. These advanced systems function as high-precision thermal perfusion units. They maintain intra-abdominal temperatures at a precise 43.0°C. This level of control optimizes chemotherapy effectiveness while protecting healthy tissue.
Bookimed Expert Insight: While Chinese manufacturers dominate the domestic market, the real differentiator is clinical volume. Fuda Cancer Hospital has served over 30,000 international patients. This high volume allows surgeons to master proprietary tools like microwave hyperthermia. This experience often leads to more refined, personalized perfusion protocols than standard settings.
Patient Consensus: Patients note it is vital to confirm if a clinic performs full cytoreductive surgery alongside HIPEC. Many emphasize asking for specific data on surgeon volume and perfusion temperatures rather than just focusing on the machine brand.
Oncology centers in China offer biological and targeted therapies alongside CRS-HIPEC for peritoneal carcinomatosis. These include PARP inhibitors for ovarian cancer and angiogenesis inhibitors like Bevacizumab. Specialized facilities often integrate immunotherapy with minimally invasive technologies. Procedures like PIPAC provide localized delivery for unresectable cases.
Bookimed Expert Insight: Chinese oncology centers like Fuda Cancer Hospital treat over 30,000 international patients. They often combine standard HIPEC with unique techniques like NanoKnife and cryosurgery. This multi-modal approach helps manage late-stage cases that are often ineligible for surgery. Specialists like Prof. Liu Shi Xin emphasize precision radiotherapy for abdominal malignancies alongside systemic drugs.
Patient Consensus: Patients note that targeted therapy isn't automatic and requires specific genetic testing for mutations like KRAS or HER2. Many advise confirming if a center has integrated medical oncology teams before starting treatment.
International patients receive carcinomatosis treatment in China at JCI-accredited oncology centers and university hospitals. These facilities specialize in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Treatment integrates Western surgical protocols with advanced ablation technologies like NanoKnife to target solid tumor metastases.
Bookimed Expert Insight: China offers a unique advantage for patients with specific solid tumor markers because it leads in CAR-T therapy trials for gastric and colorectal carcinomatosis. Hospitals like Xiamen Humanity Hospital utilize elite experts like Dr. Liu Shi Xin, who holds a State Council Special Government Allowance for oncology. Patients should prioritize clinics with dedicated peritoneal surface oncology departments rather than general cancer wards.
Patient Consensus: Patients emphasize the need for medical records to be pre-reviewed by Chinese surgical teams before traveling. They note that having on-site English-speaking coordinators and translators is vital for understanding pathology results and post-operative instructions.
Final treatment decisions for carcinomatosis in China result from shared decision-making between patients, families, and multidisciplinary medical teams. While competent adults maintain the legal right to consent, cultural norms often prioritize family consensus. Clinical experts provide specialized guidance on complex interventions like HIPEC or NanoKnife surgery.
Bookimed Expert Insight: Data from Fuda Cancer Hospital shows that treating 30,000+ international patients requires bridging different decision-making styles. While Western patients often decide individually, Chinese specialists are accustomed to detailed consultations with the family first. Choosing a JCI-accredited facility ensures that these family-driven discussions still respect international standards for informed patient consent.
Patient Consensus: Patients note that doctors in China may speak directly to relatives before sharing specific details with the patient. It is common for senior surgeons to lead the decision when choosing between aggressive surgery or palliative care.